Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 276.73K | 412.57K | 432.53K | 952.13K | 2.14M | 919.07K |
Gross Profit | -8.96K | 226.49K | -434.91K | 304.03K | 1.72M | 572.28K |
EBITDA | -3.13M | -2.13M | -1.58M | -1.07M | 185.30K | -1.13M |
Net Income | -4.46M | -3.33M | -2.68M | -1.83M | -675.80K | -2.05M |
Balance Sheet | ||||||
Total Assets | 4.20M | 6.07M | 3.65M | 3.83M | 3.89M | 3.40M |
Cash, Cash Equivalents and Short-Term Investments | 295.62K | 2.10M | 13.18K | 33.46K | -2.30M | 401.86K |
Total Debt | 9.49M | 9.56M | 9.27M | 8.30M | 11.54M | 11.91M |
Total Liabilities | 24.74M | 24.11M | 18.68M | 16.19M | 19.61M | 18.96M |
Stockholders Equity | -20.54M | -18.04M | -15.03M | -12.36M | -15.72M | -15.56M |
Cash Flow | ||||||
Free Cash Flow | -4.17M | -3.68M | -1.27M | -1.95M | -541.19K | -417.78K |
Operating Cash Flow | -3.42M | -2.94M | -1.27M | -1.88M | -504.64K | -315.90K |
Investing Cash Flow | -746.19K | -742.53K | -1.27K | -69.72K | -36.55K | -101.88K |
Financing Cash Flow | 3.61M | 5.77M | 1.25M | 1.99M | 139.32K | 730.74K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | C$65.80M | 17.06 | 14.51% | ― | 28.97% | ― | |
66 Neutral | C$41.47M | 25.43 | 5.32% | ― | -4.67% | -60.94% | |
50 Neutral | C$59.15M | ― | ― | -33.66% | -48.89% | ||
49 Neutral | AU$2.48B | 4.18 | -64.25% | 2.84% | 36.51% | 13.13% | |
43 Neutral | $92.38M | ― | -211.24% | ― | ― | 0.10% | |
33 Underperform | C$54.20M | ― | 248.46% | ― | ― | 32.71% | |
33 Underperform | C$68.96M | ― | 685.26% | ― | ― | -50.29% |
MedMira Inc. reported its second quarter financial results for FY2025, highlighting significant advancements in product launches and regulatory progress. The company introduced its Health Canada approved Multiplo® TP/HIV and Reveal® Rapid HIV Test in Canada, generating strong demand and working towards expanding its STI product portfolio. MedMira is also pursuing regulatory approvals in the U.S. for its Reveal® G4 HIV-1/2 rapid test and is in discussions to accelerate the commercialization of its MiROQ technology. Despite increased operating expenses due to clinical trials, these developments position MedMira for enhanced market access and potential growth.
MedMira Inc. has partnered with Lovell Government Services to expand access to its Reveal® G4 HIV-1/2 rapid test within federal healthcare systems, including the Veterans Health Administration and the Military Health System. This collaboration allows MedMira to leverage Lovell’s status as a Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, facilitating the procurement of their products through various federal contracting systems. The partnership is expected to enhance MedMira’s market reach and streamline the acquisition process for government agencies, thereby supporting federal procurement goals and improving healthcare delivery for veterans.
MedMira Inc. reported its Q2 FY2025 financial results, highlighting significant regulatory achievements, including Health Canada approval for its Multiplo® Rapid TP/HIV Test and Reveal® Rapid HIV Test. The company expanded its market reach through new distribution agreements in Canada and the USA. Despite recording a net loss and increased operating expenses due to clinical trials, MedMira anticipates revenue growth driven by the demand for its testing solutions. The company is also pursuing regulatory clearance for home testing applications, which could further enhance its market position.